<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AF3F030A-E3B7-4F62-8362-47B636ABF880"><gtr:id>AF3F030A-E3B7-4F62-8362-47B636ABF880</gtr:id><gtr:name>Midatech Pharma (Wales) Limited</gtr:name><gtr:address><gtr:line1>Oddfellows House,19 Newport Road</gtr:line1><gtr:city>Cardiff</gtr:city><gtr:postCode>CF24 0AA</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AF3F030A-E3B7-4F62-8362-47B636ABF880" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>AF3F030A-E3B7-4F62-8362-47B636ABF880</gtr:id><gtr:name>Midatech Pharma (Wales) Limited</gtr:name><gtr:address><gtr:line1>Oddfellows House,19 Newport Road</gtr:line1><gtr:city>Cardiff</gtr:city><gtr:postCode>CF24 0AA</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>249963.0</gtr:offerGrant><gtr:projectCost>797840.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B2337A7C-96A7-4204-B42B-9785EF6E653E"><gtr:id>B2337A7C-96A7-4204-B42B-9785EF6E653E</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720165"><gtr:id>FB513350-2BF5-4713-9D7B-400F9BD12028</gtr:id><gtr:title>Development of Prototype for innovative sustained-release pharmaceutical manufacturing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720165</gtr:grantReference><gtr:abstractText>The Pharmaceutical industry has generally been slow to innovate in formulation technologies.
Most medicines are still introduced to the body through the oral (tablets or capsules), intravenous
(soluble liquid formulations) or intra-muscular (insoluble emulsions) routes. All of
these have disadvantages especially for the increasing number of patients who require lifelong
treatments for chronic disease. As the population ages this issue becomes more important as
there is a growing cohort of patients with diabetes, COPD, Alzheimer's and so on who require
new medicines taken continually. It is difficult for patients to remember to take pills daily,
intra-venous administration can only be done under medical supervision and intra-muscular
injections are painful. A new approach to formulation is required which could handle a wide
variety of different new drugs (small molecules, peptides and biologics). Such a method
should provide for infrequent essentially pain-free injections to allow the patient to lead their
life as conveniently as possible.
Q Chip aims to address this need by developing a totally novel approach to the manufacture of
sustained-release drug formulations for sub-cutaneous injections. Such formulations are used
where a drug needs to be provided over months or years. Good examples include drugs used
to control prostate cancer, acromegaly, diabetes or schizophrenia. The Company has been
funded by investors to develop the core technology. It has been successful in this
accumulating data and establishing a clinical trial material production unit which are
attracting the attention of major pharmaceutical companies. It now needs to transfer its
technology to a manufacturing scale suitable for the production of medicines sold globally. By
extending its current IP portfolio through undertaking this research Q Chip aims to retain a
significnat part of the value of its innovation in the UK whilst aiding the developmnet of life
saving and life enhancing drugs.</gtr:abstractText><gtr:fund><gtr:end>2014-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>249963</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720165</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>